RxDoctor Payments Data

Scott Lindsay, DO

Plastic and Reconstructive Surgery · Wyomissing, PANPI 1730389206

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 60.0% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2021 at $439 and has fallen 66.8% since, to $146 in 2025. That places this record below the midpoint for plastic and reconstructive surgery clinicians in PA, where the typical reported total is $1,487.

$1,453in general payments, 2019–2025

Across 58 payments — averaging $25.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$872
  • Johnson & Johnson$138
  • Sientra, Inc.$120
  • Motiva USA, LLC$89
  • Revance Therapeutics, Inc.$78
  • KCI USA, Inc.$40
  • plus $117 from 6 others

What the payments were for

  • Food & beverage$1,453100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,453 in reported general payments places this provider in the 45th percentile of 108 plastic and reconstructive surgery providers in Pennsylvania.

See all plastic and reconstructive surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$69,454
Medicare patients
152
Services billed
469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib11$160
Cefadroxil24$138

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in Wyomissing

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →